

Preferred by surgeons for its ease of preparation, ease of handling, flexibility/pliability and tissue adherence¹

Strength and Simplicity to Seal Tissue, Stop Bleeding²⁻⁶

HEMOPATCH Application





- preparation or pre-moistening required
- Place white side of dry HEMOPATCH directly onto tissue, blue dotted side facing upwards
- Overlay multiple patches for larger surfaces



• Use a dry gauze and apply gentle, uniform pressure to HEMOPATCH for 2 minutes

SUCCESS



Improved adherence is observed when HEMOPATCH is in direct contact with wound fluid such as blood or lymphatic fluid, as demonstrated in preclinical models.

In the absence of such wound fluids, sodium bicarbonate solution (concentration between 4.2% and 8.4%) may be used in conjunction with HEMOPATCH application *Demonstrated in preclinical models

New Product Code	Product Description	Patches Per Box
1506253	HEMOPATCH 45 mm x 90 mm	3-PK
1506256	HEMOPATCH 45 mm x 45 mm	3-PK
1506257	HEMOPATCH 27 mm x 27 mm	5-PK

Baxter Healthcare S.A., Postbox, CH-8010 Zurich

HEMOPATCH comes ready to use in sterile packages and must be handled accordingly. Use only undamaged packages, single use only, do not re-sterilize. Store at room temperature (for 6 months within the shelf life).²

Indication for Use

HEMOPATCH is intended as a hemostatic device and surgical sealant for procedures in which control of bleeding or leakage of other body fluids or air by conventional surgical techniques is either ineffective or impractical. HEMOPATCH may be used to close dural defects following traumatic injury, excision, retraction or shrinkage of the dura mater. For full product information, please refer to the instructions for use.

EUMP/423/15-0029(1)a June 2017

References

- 1. Ulrich F, et al. Surg Technol Int 2016; 28:19-28.
- HEMOPATCH Sealing Hemostat Instructions for Use. Zurich, Switzerland: HEMOPATCH IFU M000423.
- 3. Fingerhut A. Surg Technol Int 2014;25:29-35.
- 4. Lewis KM, et al. ISBN Surg 2014:Mar 4:930803.doi: 10.1155/2014/930803.
- Lewis KM, et al. Int J Surg 2014;12:940-4.
- 6. Baumgartner B, et al. J Invest Surg 2016;29:343-51.





Stable, non-growing red area means successful hemostasis achieved, where necessary

• Sustained sealing and hemostasis,^{2,4–6} even in patients on antiplatelet therapy^{1,3,5,6*}

• Leave HEMOPATCH in situ to strengthen fibrin clot and aid tissue remodelling for up to 8 weeks2*

To learn more, visit www.hemopatch.com



Baxter and Hemopatch are trademarks for Baxter International Inc., its subsidiaries or affiliates.